专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20120136581A1 Method of Diagnosing Asphyxia 有权
标题翻译：诊断窒息的方法
公开(公告)号：US20120136581A1
公开(公告)日：2012-05-31
申请号：US13318797
申请日：2010-05-04
申请人： Matthias Keller , Hans-Peter Deigner , David Enot , Matthias Kohl , Ronnaug Solberg , Olga Didrik Saugstad , Therese Koal
发明人： Matthias Keller , Hans-Peter Deigner , David Enot , Matthias Kohl , Ronnaug Solberg , Olga Didrik Saugstad , Therese Koal
IPC分类号： G06F19/00
CPC分类号： G01N33/6893 , G01N2800/12 , G06F19/24 , Y02A90/26
摘要： A method for in vitro diagnosing asphyxia and disorders related thereto, a method of in vitro estimating duration of hypoxia in a patient subjected to asphyxia, and a method for in vitro monitoring of normoxic, hypoxic and hyperoxic conditions and/or normobaric and hyperbaric oxygen therapy, includes quantitatively detecting in a biological sample of a patient a plurality of asphyxia specific endogenous compounds which are selected from the group consisting of biogenic amines; carnitine-derived compounds; amino acids; bile acids; carboxylic acids; eicosanoids; lipids; precursors of cholesterol, cholesterol metabolites; prostanoids; and sugars.
摘要翻译：用于体外诊断与其相关的窒息和障碍的方法，体外估计患有窒息的患者的缺氧持续时间的方法和用于体外监测正常氧，缺氧和高氧条件和/或正常和高压氧治疗的方法包括定量检测患者的生物样品中多种选自生物胺的窒息特异性内源性化合物; 肉碱衍生化合物; 氨基酸; 胆汁酸羧酸; 类花生酸脂质胆固醇前体，胆固醇代谢物; 前列腺素和糖。

2. 发明授权

US09791459B2 Method of diagnosing and treating asphyxia 有权
公开(公告)号：US09791459B2
公开(公告)日：2017-10-17
申请号：US13318797
申请日：2010-05-04
申请人： Matthias Keller , Hans-Peter Deigner , David Enot , Matthias Kohl , Ronnaug Solberg , Ola Didrik Saugstad , Therese Koal
发明人： Matthias Keller , Hans-Peter Deigner , David Enot , Matthias Kohl , Ronnaug Solberg , Ola Didrik Saugstad , Therese Koal
IPC分类号： G01N33/48 , G01N33/68 , G06F19/24
CPC分类号： G01N33/6893 , G01N2800/12 , G06F19/24 , Y02A90/26
摘要： A method for in vitro diagnosing asphyxia and disorders related thereto, a method of in vitro estimating duration of hypoxia in a patient subjected to asphyxia, and a method for in vitro monitoring of normoxic, hypoxic and hyperoxic conditions and/or normobaric and hyperbaric oxygen therapy, includes quantitatively detecting in a biological sample of a patient a plurality of asphyxia specific endogenous compounds which are selected from the group consisting of biogenic amines; carnitine-derived compounds; amino acids; bile acids; carboxylic acids; eicosanoids; lipids; precursors of cholesterol, cholesterol metabolites; prostanoids; and sugars.

3. 发明申请

US20120208282A1 Method For Normalization in Metabolomics Analysis Methods with Endogenous Reference Metabolites. 审中-公开
标题翻译：用内源性参考代谢物代谢组学分析方法进行正常化的方法。
公开(公告)号：US20120208282A1
公开(公告)日：2012-08-16
申请号：US13381860
申请日：2010-06-23
申请人： Hans-Peter Deigner , Matthias Kohl , Matthias Keller , Therese Koal , David Enot
发明人： Hans-Peter Deigner , Matthias Kohl , Matthias Keller , Therese Koal , David Enot
IPC分类号： G01N27/62 , G01R33/465
CPC分类号： G16B40/00 , G01N2800/60 , Y10T436/163333 , Y10T436/201666
摘要： The present invention relates to the use of endogenous reference metabolites and a method for normalization of intensity data corresponding to amounts and/or concentrations of selected target metabolites in a biological sample of a mammalian subject, wherein said intensity data are obtained by a metabolomics analysis method with one or a plurality of endogenous reference metabolites, comprising carrying out at least one in vitro metabolomics analysis method of said selected target metabolites in said biological sample, simultaneously carrying out in the same sample a quantitative analysis of one or a plurality of endogenous reference metabolites or derivatives thereof, wherein said endogenous reference metabolites are such compounds in the biological sample which are present in the subject at an essentially constant level; and wherein said endogenous reference metabolites or derivatives thereof have a molecular mass less than 1500 Da.
摘要翻译：本发明涉及内源性参考代谢物的使用以及对应于哺乳动物受试者的生物样品中所选靶标代谢物的量和/或浓度的强度数据的归一化方法，其中所述强度数据通过代谢组学分析法与一种或多种内源性参考代谢物，包括在所述生物样品中进行所述选择的目标代谢物的至少一种体外代谢组学分析方法，同时在同一样品中进行一种或多种内源性参考代谢物的定量分析或其衍生物，其中所述内源性参考代谢物是生物样品中以基本恒定水平存在于受试者中的这样的化合物; 并且其中所述内源性参考代谢物或其衍生物具有小于1500Da的分子量。

4. 发明申请

US20120115138A1 METHOD FOR IN VITRO DIAGNOSING A COMPLEX DISEASE 审中-公开
标题翻译：用于诊断复杂疾病的方法
公开(公告)号：US20120115138A1
公开(公告)日：2012-05-10
申请号：US13263429
申请日：2010-03-31
申请人： Hans-Peter Deigner , Matthias Kohl , Matthias Keller , Therese Koal , Klaus Wwinberger
发明人： Hans-Peter Deigner , Matthias Kohl , Matthias Keller , Therese Koal , Klaus Wwinberger
IPC分类号： C12Q1/68 , G01N33/53
CPC分类号： C12Q1/6886 , C12Q2600/158 , C12Q2600/178 , G16B20/00 , G16B25/00 , G16B40/00 , G16B50/00
摘要： The present invention relates to a method and kit for in vitro diagnosing a complex disease such as cancer, in particular, acute myeloid leukemia (AML), colon cancer, kidney cancer, prostate cancer; transient ischemic attack (TIA), ischemia, in particular stroke, hypoxia, hypoxic-ischemic encephalopathy, perinatal brain damage, hypoxic-ischemic encephalopathy of neotatals asphyxia; demyelinating disease, in particular, white-matter disease, periventricular leukoencephalopathy, multiple sclerosis, Alzheimer and Parkinson's disease; in a biological sample. For the diagnosis, use is made of measuring at least two different species of biomolecules and classifying the results by means of suitable classifier algorithms and other statistical procedures. With the present invention, a significant improvement of the reliability of e.g. expression profiles alone, are achieved. In other words, in a defined collective, an up to 100% accurate positive diagnosis could be achieved, which renders the method of the present invention superior over the prior art.
摘要翻译：本发明涉及用于体外诊断复杂疾病如癌症，特别是急性骨髓性白血病（AML），结肠癌，肾癌，前列腺癌的方法和试剂盒; 短暂性脑缺血发作（TIA），缺血，特别是中风，缺氧，缺氧缺血性脑病，围产期脑损伤，缺氧缺血性脑病的新生儿窒息; 脱髓鞘疾病，特别是白质病，脑室周围脑白质病，多发性硬化，阿尔茨海默病和帕金森病; 在生物样品中。对于诊断，使用测量至少两种不同种类的生物分子，并通过适当的分类器算法和其他统计程序对结果进行分类。通过本发明，可以显着提高可靠性。单独表达谱。换句话说，在定义的集体中，可以实现高达100％的准确的阳性诊断，这使得本发明的方法优于现有技术。

5. 发明申请

US20120202240A1 Method for Predicting the likelihood of an Onset of an Inflammation Associated Organ Failure 审中-公开
标题翻译：预测炎症相关器官衰竭发生的可能性的方法
公开(公告)号：US20120202240A1
公开(公告)日：2012-08-09
申请号：US13387572
申请日：2010-07-23
申请人： Hans-Peter Deigner , Matthias Kohl , David Enot , Theresa Koal , Matthias Keller
发明人： Hans-Peter Deigner , Matthias Kohl , David Enot , Theresa Koal , Matthias Keller
IPC分类号： G01N27/62 , G01R33/48 , G06F19/00 , H01J49/26 , G01N27/72
CPC分类号： G01N33/6893 , G01N2800/26 , G16B5/00 , G16B40/00 , Y10T436/173845
摘要： The present invention relates to a reliable and statistically significant method for predicting the likelihood of an onset of an inflammation associated organ failure from a biological sample of a mammalian subject in vitro, by means of a subject's quantitative metabolomics profile comprising a plurality of endogenous metabolites, and comparing it with a quantitative reference metabolomics profile of a plurality of endogenous organ failure predictive target metabolites in order to predict whether the subject is likely or unlikely to develop an organ failure. Furthermore, the invention relates to the usefulness of endogenous organ failure predictive target metabolites in such a method.
摘要翻译：本发明涉及用于通过受试者的定量代谢组学谱来预测来自哺乳动物受试者的体外生物样品的炎症相关器官功能衰竭发作的可能性的可靠和统计学上显着的方法，所述定量代谢组学特征包括多种内源性代谢物，并将其与多种内源性器官衰竭预测目标代谢物的定量参考代谢组学谱进行比较，以便预测受试者是否可能或不可能发生器官功能衰竭。此外，本发明涉及在这种方法中内源性器官衰竭预测目标代谢物的有用性。

6. 发明申请

US20140297195A1 Method and Use of Metabolites for the Diagnosis of Inflammatory Brain Injury in Preterm Born Infants 审中-公开
标题翻译：代谢产物诊断早产儿炎症性脑损伤的方法与用途
公开(公告)号：US20140297195A1
公开(公告)日：2014-10-02
申请号：US14000931
申请日：2012-02-22
申请人： Matthias Keller , Carina Mallard , Hans-Peter Deigner , David Enot , Emeka I. Igwe
发明人： Matthias Keller , Carina Mallard , Hans-Peter Deigner , David Enot , Emeka I. Igwe
IPC分类号： G06F19/10 , G01N33/483
CPC分类号： G16B99/00 , G01N33/483 , G01N33/6896 , G01N2800/38
摘要： The present invention relates to novel biomarkers for predicting the likelihood of inflammation-related brain injury in preterm born infants, using a plurality of endogenous target metabolites selected from the group consisting of acyl carnitins, diacylphosphatidylcholines, acyl-alkylphosphatidylchoines, lysophosphatidylcholines and amino acids.
摘要翻译：本发明涉及使用选自酰基肉毒碱，二酰基磷脂酰胆碱，酰基 - 烷基磷脂酰胆碱，溶血磷脂酰胆碱和氨基酸的多种内源性目标代谢物来预测早产儿婴幼儿发炎相关脑损伤的可能性的新型生物标志物。

7. 发明申请

US20120326025A1 DIAGNOSING PROSTATE CANCER RELAPSE 审中-公开
标题翻译：诊断前列腺癌相关
公开(公告)号：US20120326025A1
公开(公告)日：2012-12-27
申请号：US13575903
申请日：2011-01-28
申请人： Klaus Weinberger , Hans-Peter Deigner , Emeka Ignatius Igwe , David Enot , Guido Dallmann , Helmut Klocker
发明人： Klaus Weinberger , Hans-Peter Deigner , Emeka Ignatius Igwe , David Enot , Guido Dallmann , Helmut Klocker
IPC分类号： H01J49/26
CPC分类号： G01N33/57434 , G01N2800/54
摘要： The invention discloses the use of at least one substance selected from the group consisting of Phosphatidylcholine with diacyl residue sum C24:0 (PC aa C24:0); Phosphatidylcholine with diacyl residue sum C40:3 (PC ae C40:3); Phosphatidylcholine with diacyl residue sum C40:4 (PC ae C40:4); Lysophosphatidylcholine with acyl residue sum C26:0 (lysoPC a C26:0); Lysophosphatidylcholine with acyl residue sum C6:0 (lysoPC a C6:0); 13(S)-hydroxy-9Z,11E-octadecadienoic acid (13S-HODE); 12(S)-hydroxy-5Z,8Z,10E,14Z-eicosatetraenoic acid (12S-HETE); 15(S)-hydroxy-5Z,8Z,11Z,13E-eicosatetraenoic acid (15S-HETE); Leukotriene B4 (LTB4); Prostaglandin E2 (PGE2); Prostaglandin D2 (PGD2); 7α-Hydroxycholesterol (7aOHC); 7-Ketocholesterol (7KC); 5β,6β-Epoxycholesterol (5b,6b,EPC); 5g302,6g302-Epoxycholesterol (5a,6a,EPC); and 4β-Hydroxycholesterol (4BOHC); for prognosticating relapse of a prostate cancer (PCa) in a sample of a body fluid or a tissue sample of a PCa patient.
摘要翻译：本发明公开了使用选自由二酰基残基和C24：0（PCaa C24：0）组成的组的至少一种物质; 具有二酰基残基总数C40：3的磷脂酰胆碱（PC ae C40：3）; 具有二酰基残基的磷脂酰胆碱总数C40：4（PC ae C40：4）; 酰基残基总数为C26：0的溶血磷脂酰胆碱（lysoPC a C26：0）; 具有酰基残基的溶血磷脂酰胆碱和C6：0（溶血糖素a C6：0）; 13（S） - 羟基-9Z，11E-十八碳二烯酸（13S-HODE）; 12（S） - 羟基-5Z，8Z，10E，14Z-二十碳四烯酸（12S-HETE）; 15（S） - 羟基-5Z，8Z，11Z，13E-二十碳四烯酸（15S-HETE）; 白三烯B4（LTB4）; 前列腺素E2（PGE2）; 前列腺素D2（PGD2）; 7α-羟基胆固醇（7aOHC）; 7-酮胆固醇（7KC）; 5＆bgr;，6＆bgr; - 环氧胆固醇（5b，6b，EPC）; 5g302,6g302-环氧胆固醇（5a，6a，EPC）; 和4＆bgr; - 羟基胆固醇（4BOHC）; 用于预测PCa患者体液或组织样品中前列腺癌（PCa）的复发。

8. 发明申请

US20080070235A1 Method for Recognizing Acute Generalized Inflammatory Conditions (Sirs), Sepsis, Sepsis-Like Conditions and Systemic Infections 审中-公开
标题翻译：识别急性广泛性炎症病症（Sirs）的方法，败血症，脓毒症状况及全身感染
公开(公告)号：US20080070235A1
公开(公告)日：2008-03-20
申请号：US10551874
申请日：2004-03-31
申请人： Stefan Russwurm , Konrad Reinhart , Hans-Peter Saluz , Eberhard Straube , Peter Zipfel , Hans-Peter Deigner
发明人： Stefan Russwurm , Konrad Reinhart , Hans-Peter Saluz , Eberhard Straube , Peter Zipfel , Hans-Peter Deigner
IPC分类号： C12Q1/68 , C12P19/34
CPC分类号： C12Q1/6883 , B82Y5/00 , B82Y10/00 , C12Q1/6837 , C12Q2600/158 , Y10T436/143333
摘要： The present invention relates to a method for in vitro detection of SIRS, sepsis and/or sepsis-like conditions. This method renders the evaluation of the severity and/or the therapeutic progress of sepsis and severe infections, in particular sepsis-like systemic infections possible. Further, the present invention relates to the use of recombinantly or synthetically prepared nucleic acid sequences or peptide sequences derived therefrom as calibrator in sepsis assays and/or for the evaluation of the effect and the toxicity during screening of the active agents and/or the preparation of therapeutics for the prevention and treatment of SIRS, sepsis, sepsis-like systemic inflammatory conditions and sepsis-like systemic infections.
摘要翻译：本发明涉及一种用于体外检测SIRS，败血症和/或脓毒病样条件的方法。该方法可以评估败血症和严重感染的严重性和/或治疗进展，特别是脓毒症样全身感染。此外，本发明涉及重组或合成制备的核酸序列或其衍生的肽序列作为脓毒症测定中的校准物和/或用于评估活性剂和/或制剂筛选过程中的作用和毒性的用途用于预防和治疗SIRS，败血症，败血症样全身性炎症病症和败血症样全身感染的治疗剂。

9. 发明授权

US08481262B2 Method for enriching and/or separating prokaryotic DNA using a protein that specifically bonds to unmethylated DNA containing CpG-motifs 失效
标题翻译：使用特异性结合含有CpG基序的未甲基化DNA的蛋白质来富集和/或分离原核DNA的方法
公开(公告)号：US08481262B2
公开(公告)日：2013-07-09
申请号：US10591633
申请日：2005-03-02
申请人： Karl-Hermann Schmidt , Eberhard Straube , Stefan Russwurm , Hans-Peter Deigner , Svea Sachse , Marc Lehmann
发明人： Karl-Hermann Schmidt , Eberhard Straube , Stefan Russwurm , Hans-Peter Deigner , Svea Sachse , Marc Lehmann
IPC分类号： C12Q1/68 , C07H21/04 , C07K14/00
CPC分类号： C12N15/1006 , C12N15/1003
摘要： The invention relates to a method for separating and/or enriching prokaryotic DNA, comprising the following steps: a) contacting of at least one prokaryotic DNA that is in solution with a protein that bonds specifically to prokaryotic DNA, the protein being 25%-35% homologous with the wild-type CGPB protein, thus forming a protein-DNA complex; and b) separation of the complex. The invention also relates to a kit for carrying out said method.
摘要翻译：本发明涉及分离和/或富集原核DNA的方法，包括以下步骤：a）将至少一种在溶液中的原核DNA与特异性结合于原核DNA的蛋白质接触，所述蛋白质为25％-35 与野生型CGPB蛋白质同源，从而形成蛋白质-DNA复合物; 和b）复合物的分离。本发明还涉及一种用于执行所述方法的套件。

10. 发明申请

US20080003568A1 Method for Enriching and/or Separating Prokaryotic Dna Using a Protein that Specifically Bonds to Unmethylated Dna Containing Cpg-Motives 失效
标题翻译：使用特异性结合含有Cpg动机的非甲基化Dna的蛋白质来丰富和/或分离原核Dna的方法
公开(公告)号：US20080003568A1
公开(公告)日：2008-01-03
申请号：US10591633
申请日：2005-03-02
申请人： Karl-Hermann Schmidt , Eberhard Straube , Stefan Russwurm , Hans-Peter Deigner , Svea Sachse , Marc Lehmann
发明人： Karl-Hermann Schmidt , Eberhard Straube , Stefan Russwurm , Hans-Peter Deigner , Svea Sachse , Marc Lehmann
IPC分类号： C12N1/08 , C12Q1/68
CPC分类号： C12N15/1006 , C12N15/1003
摘要： The invention relates to a method for separating and/or enriching prokaryotic DNA, comprising the following steps: a) contacting of at least one prokaryotic DNA that is in solution with a protein that bonds specifically to prokaryotic DNA, said protein being 25%-35% homologous with the wild-type CGPB protein, thus forming a protein-DNA complex; and b) separation of the complex. The invention also relates to a kit for carrying out said method.
摘要翻译：本发明涉及分离和/或富集原核DNA的方法，包括以下步骤：a）将至少一种在溶液中的原核DNA与特异性结合于原核DNA的蛋白质接触，所述蛋白质为25％-35 与野生型CGPB蛋白质同源，从而形成蛋白质-DNA复合物; 和b）复合物的分离。本发明还涉及一种用于执行所述方法的套件。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式